Skip to main content
SpringerLink
Log in

Mazaticol for Treating Parkinson

  • Living reference work entry
  • First Online:
Book cover NeuroPsychopharmacotherapy

  • 157 Accesses

Abstract

Mazaticol, 6,6,9-trimethyl-9-azabicyclo[3,3,1]non-3β-yl-α,α-di-(2-thienyl) glycolate hydrochloride monohydrate, was developed by Tanabe Seiyaku Co. LTD. in1970s and started selling in 1978 in Japan. This agent has an anticholinergic activity in the central nervous system as the same degree of well-known anticholinergic medicine, trihexyphenidyl. Mazaticol and other anticholinergic agents are considered to block the muscarinic acetylcholine receptors and cholinergic nerve activity. Mazaticol has an affinity to M1 and M2 muscarinic acetylcholine receptor and had less peripheral activity compared to other anticholinergic agents. In the animal experiments, mazaticol exhibited inhibitory effects on dopamine uptake in the striatal nerve terminal. As for clinical indication, mazaticol is applied mainly to a psychotropic drug-induced parkinsonian syndrome. Many clinical evaluations showed efficacy of mazaticol is almost as same as the other anticholinergic agents. But mazaticol showed the improvement of symptoms for the cases in which other drugs had no effects. However, current clinical studies on mazaticol are not enough, especially for the idiopathic parkinsonian disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Fujimura K. Pakinson syoukougun ni taisuru pentona to sinmetoreru tono moukenhou ni yoru yakkou hikaku. J New Rem Clin. 1976;25(11):1917–20.

    Google Scholar 

  • Gomeza J, Shannon H, Kostenis E, Felder C, Zhang L, Grinberg A, Sheng H, Wess J. Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci U S A. 1999;96(4):1692–7.

    Article  CAS  Google Scholar 

  • Inada T, Inagaki A. Psychotropic dose equivalence in Japan. Psychiatry Clin Neurosci. 2015;69(8):440–7.

    Article  Google Scholar 

  • Katayama S, Ishizaki F, Yamamura Y, Khoriyama T, Kito S. Effects of anticholinergic antiparkinsonian drugs on binding of muscarinic receptor subtypes in rat brain. Res Commun Chem Pathol Pharmacol. 1990;69:261–70.

    CAS  PubMed  Google Scholar 

  • Kawai Y, Noguchi M, Noguchi Y. Chronic toxicity study of an antiparkinsonian agent, 6,6,9-trimethyl-9-azabicyclo 3,3,1non-3β-yl α,α-di(2-thienyl) glycolate hydrochloride monohydrate (PG-501) in rats. Pharmacometrics. 1974;9:1305–10.

    Google Scholar 

  • Kosaka K. The beneficial effect of PG-501 on parkinsonism. Rinsho yakuri/Jpn J Clin Pharmacol Ther. 1971;2(3):230–5.

    Article  Google Scholar 

  • Meshi T, Nakamura S, Sato Y. Metabolic fate of 6, 6, 9-trimethyl-9-ayabicyclo[3, 3, 1]non-3β-yl α, α-di(2-thienyl) glycolate hydrochloride monohydrate (PG-501). Chem Pharm Bull. 1972;8:1687–98.

    Article  Google Scholar 

  • Nakajima H, Matsuda Y. Yakuzaise pa-kinson syoukougun ni taisuru ensan mazatiko-ru (pentona®) no tiryou keiken. Clin Rep. 1986;20(2):1325–33.

    Google Scholar 

  • Nose T, Kojima M, Isida R, Shintomi K, Kowa Y. Pharmacological properties of 6, 6, 9-trimethyl-9-ayabicyclo[3, 3, 1]non-3β-ylα, α-di(2-thienyl) glycolate hydrochloride monohydrate (PG-501), a new anti-parkinsonian agent. Folia Pharmacol Japan. 1971;67:387–405.

    Article  CAS  Google Scholar 

  • Otsuka M, Nakamura S, Sato Y. Absorption, distribution and excretion of 14C-labelled 6, 6, 9-trimethyl-9-ayabicyclo[3, 3, 1]non-3β-ylα, α-di(2-thienyl) Glycolate hydrochloride monohydrate (PG-501). Yakugaku Zasshi (in Japanese). 1972;8:986–96.

    Article  Google Scholar 

  • Pharmaceutical products interview form in Japan. 2015. https://medical.mt-pharma.co.jp/di/file/if/f_pnt.pdf. Accessed 29 Aug 2017.

  • Saito M, Kita S, Kagono Y, Suitsu N, Honda Y. Computerized EEG study on drug-induced extrapyramidalism in schizophrenic patients. Electroencephalogr Clin Neurophysiol Suppl. 1982;36:524–37.

    CAS  PubMed  Google Scholar 

  • Suitsu N. A computer-assisted EEG study on psychotropic properties of antiparkinsonian drugs. Seishin Shinkeigaku Zasshi (in Japanese). 1992;94(3):238–62.

    CAS  Google Scholar 

  • Takesada, Sakai T, Tutsumi S, Isoda K, Kondo H, Hujimura K, Iwatani N, Yamauchi I, Kato N. Pa-kinson syoukougun ni taisuru Mazaticol・HCl oyobi Amantidine・HCl no koukahikaku. Jpn J Clin Exp Med (in Japanese). 1977;54(5):1655–67.

    Google Scholar 

  • Tanaka R, Ogata M, Honda O, Kinokuni U, Okamoto Y, Yagu S, Sakaoka U, Sanada H, Teraoka M, Kuji K. Effects of PG-501 on Parapyramidal system syndrome induced by Psychotropics. Med Consult New Remedies. 1972;9(3):641–6.

    Google Scholar 

  • Yagi G, Yauchi N, Tokizawa T, Tashiro I, Takeda A, Sakurai S, Kobayashi T, Itou A. Yakubutusei suitaigairo syoujyou ni taisuru mazaticol hydrochloride, Trihexyphenidyl oyobi promethazine no koukahikaku – double-blind cross-over Mehtod no niyoru kentou. Jpn J Clin Psychiatry (in Japanese). 1973;2(11):1311–38.

    Google Scholar 

  • Yamaguchi K, Ishihara H, Ariyuki F, Noguchi Y, Kowa Y. Teratological study of 6,6,9-Trimethyl-9-azabicyclo (3,3,1) non-3β-yl α,α-di-(2-thienyl) glycolate hydrochloride monohydrate (PG-501). Pharmacometrics. 1974;8(8):1213–8.

    CAS  Google Scholar 

  • Yukawa E, Hokazono T, Yukawa M, Ichimaru R, Maki T, Matsunaga K, Ohdo S, Anai M, Higuchi S, Goto Y. Population pharmacokinetics of haloperidol using routine clinical pharmacokinetic data in Japanese patients. Clin Pharmacokinet. 2002;41(2):153–9.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology and Neuroscience, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

    Yoshiki Niimi & Tatsuro Mutoh

Authors
  1. Yoshiki Niimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tatsuro Mutoh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tatsuro Mutoh .

Editor information

Editors and Affiliations

  1. Dept Psychiatry , Psychosomatics & Psychotherapy, University of Würzburg, Medical School Clinical Neurochemistry, Würzburg, Germany

    Peter Riederer

  2. Inst für Psychologische Medizin, Haag, Bayern, Germany

    Gerd Laux

  3. Department of Psychiatry, University of Toronto Department of Psychiatry, Toronto, ON, Canada

    Benoit Mulsant

  4. Center Translational Res Neurol Diseases, Dalian Med Uni Shanghai Inst Health Sc Center Translational Res Neurol Diseases, Dalian, China

    Weidong Le

  5. Fujita Health University School Medicine, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

Section Editor information

  1. Fujita Health University School of Medicine, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

  2. Institute of Environmental Medicine, Nagoya University, Nagoya, Aichi, Japan

    Toshiharu Nagatsu

  3. Department of Physiological Chemistry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

    Akira Nakashima

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Niimi, Y., Mutoh, T. (2020). Mazaticol for Treating Parkinson. In: Riederer, P., Laux, G., Mulsant, B., Le, W., Nagatsu, T. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_362-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56015-1_362-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56015-1

  • Online ISBN: 978-3-319-56015-1

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation